Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration

Pierluigi Iacono, Maurizio B. Parodi, Ugo Introini, Carlo La Spina, Monica Varano, Francesco Bandello

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

PURPOSE: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration. METHODS: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 μm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 μm (P <0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered. CONCLUSION: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalRetina
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Hemorrhage
Visual Acuity
Intravitreal Injections
Injections
Optical Coherence Tomography
Ranibizumab
Therapeutics

Keywords

  • Age-related macular degeneration
  • Anti-VEGF
  • Intravitreal ranibizumab
  • Subfoveal choroidal neovascularization

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration. / Iacono, Pierluigi; Parodi, Maurizio B.; Introini, Ugo; La Spina, Carlo; Varano, Monica; Bandello, Francesco.

In: Retina, Vol. 34, No. 2, 02.2014, p. 281-287.

Research output: Contribution to journalArticle

@article{6979ae788576401faabf14bb30e2b616,
title = "Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration",
abstract = "PURPOSE: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration. METHODS: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50{\%} of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 μm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 μm (P <0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered. CONCLUSION: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.",
keywords = "Age-related macular degeneration, Anti-VEGF, Intravitreal ranibizumab, Subfoveal choroidal neovascularization",
author = "Pierluigi Iacono and Parodi, {Maurizio B.} and Ugo Introini and {La Spina}, Carlo and Monica Varano and Francesco Bandello",
year = "2014",
month = "2",
doi = "10.1097/IAE.0b013e3182979e33",
language = "English",
volume = "34",
pages = "281--287",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration

AU - Iacono, Pierluigi

AU - Parodi, Maurizio B.

AU - Introini, Ugo

AU - La Spina, Carlo

AU - Varano, Monica

AU - Bandello, Francesco

PY - 2014/2

Y1 - 2014/2

N2 - PURPOSE: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration. METHODS: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 μm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 μm (P <0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered. CONCLUSION: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

AB - PURPOSE: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration. METHODS: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 μm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 μm (P <0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered. CONCLUSION: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

KW - Age-related macular degeneration

KW - Anti-VEGF

KW - Intravitreal ranibizumab

KW - Subfoveal choroidal neovascularization

UR - http://www.scopus.com/inward/record.url?scp=84893304766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893304766&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3182979e33

DO - 10.1097/IAE.0b013e3182979e33

M3 - Article

C2 - 23851632

AN - SCOPUS:84893304766

VL - 34

SP - 281

EP - 287

JO - Retina

JF - Retina

SN - 0275-004X

IS - 2

ER -